Performance of New Roche Cobas Pulse Glucose Meter Against Potential Interfering Substances and Hematocrit Variations
Diagnostics · 01.05.2026 · 16 (9) · 1383
DOI: 10.3390/diagnostics16091383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 01.05.2026. Verfasst von Mokarrameh Pudineh Moarref und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Dr. Everett Chalmers Regional Hospital, Horizon Health Network, Fredericton, NB E3B 5N5, Canada. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Point-of-care (POC) glucometers are essential for rapid blood glucose monitoring but are subject to interference and hematocrit variations. This study evaluated the analytical performance of the new Cobas Pulse glucometer against the Accu-Chek Inform II meter in the presence of N-acetylcysteine (NAC, 0.32–2.5 mmol/L), ascorbic acid (0.28–2.84 mmol/L), D-galactose (5.5–27 mmol/L), hemolysis (0.5–5 g/L hemoglobin), icterus (200–1600 μmol/L bilirubin), lipemia (2.5–15 g/L Intralipid), and hematocrit variations (20–60%).
Methods
Interference testing followed CLSI EP07 guidelines using three whole blood pools with low (2.0–2.7 mmol/L), medium (4.5–7.4 mmol/L), and high (16.3–23 mmol/L) glucose levels. Interferents were spiked into these whole blood pools. Duplicate glucose levels were measured by 2 Pulse meters and 2 Inform II meters. The results were then assessed using the international standards, e.g., ISO 15197:2017 criteria (±15% or ±0.83 mmol/L).
Results
Accu-Chek Inform II showed severe positive interference from galactose (up to 446.3%, p < 0.001), ascorbic acid (up to 98.8%, p = 0.002), and NAC (up to 61.4%, p = 0.001), exceeding ISO limits. Cobas Pulse demonstrated minimal interference (maximum biases: −3.7% for galactose, −4.4% for ascorbic acid, 7.7% for NAC, all p > 0.05). Both meters showed similar hematocrit-dependent bias (positive at 20–30%, negative at 50–60%) and acceptable performance for hemolysis, icterus (≤800 μmol/L), and lipemia.
Conclusions
Compared to the Accu-Chek Inform II, the Cobas Pulse demonstrated greater resilience to interferences. Cobas Pulse meets strict accuracy standards (±10% for hospital use) with low interference, which makes it suitable for care of critically ill patients. The Cobas Pulse is more dependable for POCT across various clinical situations, supporting its role in critical care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Dr. Everett Chalmers Regional Hospital, Horizon Health Network, Fredericton, NB E3B 5N5, Canada.
- Department of Pathology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
- Discipline of Laboratory Medicine, Memorial University of Newfoundland, St. John's, NL A1B 3V6, Canada.
ORCID-Profile: Yu Chen
Zitieren
APA
Pudineh Moarref, M., Black, W., & Chen, Y. (2026). Performance of New Roche Cobas Pulse Glucose Meter Against Potential Interfering Substances and Hematocrit Variations. Diagnostics, 16(9), 1383. https://doi.org/10.3390/diagnostics16091383
Vancouver
Pudineh Moarref M, Black W, Chen Y. Performance of New Roche Cobas Pulse Glucose Meter Against Potential Interfering Substances and Hematocrit Variations. Diagnostics. 2026;16(9):1383. doi:10.3390/diagnostics16091383
BibTeX
@article{PudinehMoarref2026,
author = {Pudineh Moarref, Mokarrameh and Black, Wanda and Chen, Yu},
title = {Performance of New Roche Cobas Pulse Glucose Meter Against Potential Interfering Substances and Hematocrit Variations},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {9},
pages = {1383},
doi = {10.3390/diagnostics16091383}
}
EUVIMED